Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia

TA29 Leukaemia (lymphocytic) - fludarabine: Summary information

TA29 Leukaemia (lymphocytic) - fludarabine: Summary (PDF 39 KB)

TA29 Leukaemia (lymphocytic) - fludarabine: Guidance (html) information

TA29 Leukaemia (lymphocytic) - fludarabine: review decision - December 2013 information

TA29 Leukaemia (lymphocytic) - fludarabine: Appendix A - decision paper presented to the Institute's Guidance Executive (PDF 106 KB)

TA29 Leukaemia (lymphocytic) - fludarabine: review proposal - October 2013 information

Appendix A: provisional matrix of stakeholders (PDF 104 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 270 KB)

Review decision information

Review proposal information

Fludarabine as second line therapy for B-cell chronic lymphocytic leukaemia: Cost-effectiveness annexe  information

Fludarabine as second line therapy for B-cell chronic lymphocytic leukaemia: Cost-effectiveness annexe (PDF 32 KB)

Fludarabine as second line therapy for B-cell chronic lymphocytic leukaemia: Effectiveness annexe  information

Fludarabine as second line therapy for B-cell chronic lymphocytic leukaemia: Effectiveness annexe (PDF 126 KB)

Fludarabine as second line therapy for B-cell chronic lymphocytic leukaemia - HTA report (main)  information

Fludarabine as second line therapy for B-cell chronic lymphocytic leukaemia - HTA report (main) (PDF 285 KB)